Synthesis and trypanocidal activity of novel pyridinyl-1,3,4-thiadiazole derivatives - 30/05/20

pages | 14 |
Iconographies | 13 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | New N-aminobenzyl or N-arylhydrazone 1,3,4-thiadiazole derivatives were synthesized. |
• | Target compounds were designed as analogues of CYP51 inhibitors. |
• | 1,3,4-Thiadiazoles showed trypanocidal action in trypomastigote forms of T. cruzi. |
• | Compound 11a produced phenotypic changes similar to those caused by posaconazole. |
• | Hydrochloride 11a can be considered as a good trypanocidal drug candidate. |
Abstract |
Herein, we present the design, synthesis and trypanocidal evaluation of sixteen new 1,3,4-thiadiazole derivatives from N-aminobenzyl or N-arylhydrazone series. All derivatives were assayed against the trypomastigote form of Trypanosoma cruzi, showing IC50 values ranging from 3 to 226 μM, and a better trypanocidal profile was demonstrated for the 1,3,4-thiadiazole-N-arylhydrazones (3a-g). In this series, the 2-pyridinyl fragment bound to the imine subunit of the hydrazine moiety presented pharmacophoric behavior for trypanocidal activity. Compounds 2a, 11a and 3e presented remarkable activity and excellent selectivity indexes. Compound 2a was also active against the intracellular amastigote form of T. cruzi. Moreover, its corresponding hydrochloride, compound 11a, showed the most promising profile, producing phenotypic changes similar to those caused by posaconazole, a well-known inhibitor of sterol biosynthesis. Thus, 1,3,4-thiadiazole derivative 11a could be considered a good prototype for the development of new drug candidates for Chagas disease therapy.
Le texte complet de cet article est disponible en PDF.Keywords : Chagas disease, Trypanocidal activity, Inhibitor of sterol biosynthesis, 2-amino-1,3,4-thiadiazole, 1,3,4-thiadiazole-N-arylhydrazone
Plan
Vol 127
Article 110162- juillet 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?